Gamida Cell’s (NASDAQ: GMDA) share price has jumped 19% after the company announced data from its Phase 3 study of omidubicel.
The company said that the drug is an investigational advances cell therapy and could be used as a “potential life-saving treatment option for patients in need of bone marrow transplant.” The study met its primary endpoint as well as all three of its secondary endpoints.
Julian Adams, Ph.D., chief executive officer of Gamida Cell, stated that the additional data “reinforce the potential of omidubicel and move us another step closer toward bringing potentially curative therapies to patients.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Gamida said that they are continuing to work to enable the submission of its biologics license application for omidubicel to the FDA, which is expected in the fourth quarter.
Gamida Cell stock…
Gamida’s share price has jumped premarket on Tuesday since the news was announced. After closing Monday’s session at $4.20, shares are now priced at $4.80, up 14%.
PEOPLE WHO READ THIS ALSO VIEWED:
